MARX Biotech Co., Ltd. (TPEX:7731)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Retail - Drugs	618.23M	289.93M	110.64M
Retail - Drugs Growth	113.24%	162.04%	-
Total	618.23M	289.93M	110.64M
Total Growth	113.24%	162.04%	-

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Taiwan	615.54M	284.62M	104.45M
Taiwan Growth	116.27%	172.49%	-
China	1.03M	3.30M	4.39M
China Growth	-68.87%	-24.70%	-
Singapore and Malaysia	1.66M	2.00M	1.80M
Singapore and Malaysia Growth	-17.09%	10.92%	-
Total	618.23M	289.93M	110.64M
Total Growth	113.24%	162.04%	-

Source: S&P Global Market Intelligence.